ClinicalTrials.gg
CompletedNCT01507246IMPROVE-OpenUpdated May 8, 2013Results posted

Adult Patients Undergoing Open Colectomy MA402S23B303

A Phase 4 interventional study of IV morphine sulfate and EXPAREL (bupivacaine liposome injectable suspension) in Bowel Obstruction, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-08.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Intestinal Obstruction with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Intestinal Obstruction · United States.

Enrollment
9th of 16
42 · median 59
Started
2011
with 1 other
Phase 4
5 of 29
none open now
Registered
8th of 29
by date
Lead sponsor
4 of 29
Pacira Pharmaceuticals, Inc

Among the 29 studies in Intestinal Obstruction with a site in United States, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 4, and was the 8th registered.

Intestinal Obstruction

105 studies on the registry are indexed under Intestinal Obstruction; 16 are open to participants now.

Browse Intestinal Obstruction studies →

Open to participants now

2 of the 29 studies in Intestinal Obstruction with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Intestinal Obstruction studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Intestinal Obstruction with a site in United States, or all of them as a file.
02

Study summary

This study is designed to compare the standard of care against EXPAREL(R) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Read the detailed description

This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL compared with postsurgical administration of standardized intravenous (IV) morphine sulfate or sponsor-approved equivalent for postsurgical analgesia in adult patients undergoing open colectomy with general anesthesia.

03

Conditions studied

  • Bowel Obstruction

Keywords

  • open colectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age and older.
  • Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.
  • Ability to provide , adhere to study visit schedule, and complete all assessments.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.
  • Patients who abuse alcohol or other drug substance.
  • Patients with severe hepatic impairment.
  • Patients currently pregnant or who may become pregnant during the course of the study.
  • Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.
  • Patients who have participated in an EXPAREL study within the last 30 days.
  • Patients who have received an drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.
  • Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery

In addition, the patient will be ineligible if he/she meets the following criteria during surgery:

  • Patients who have any concurrent surgical procedure.
  • Patients with unplanned multiple segmental resections or large intestine.
  • Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.
  • Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents.
  • Patients who receive Entereg(R).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    IV morphine sulfate

    Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.

    Drug: IV morphine sulfate

  • Experimental
    EXPAREL (bupivacaine liposome injectable suspension)

    EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.

    Drug: EXPAREL (bupivacaine liposome injectable suspension)

Interventions

  • Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.

    Also known as: morphine sulfate (or Sponsor-approved equivalent)

  • Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care. All patients will be offered rescue analgesia, as needed.

    Also known as: bupivacaine free base

06

What researchers measure

Primary outcomes

  1. Total Opioid Burden

    Total opioid consumed (IV and PO) postsurgically until the hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order written or Day 30, whichever is sooner

  2. Health Economic Benefits - Total Cost of Hospitalization

    Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order written or Day 30, whichever is sooner.

  3. Health Economic Benefits - Length of Stay

    Length of stay (LOS), recorded in hours and converted to days with one decimal of precision, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Up to Day 30

Secondary outcomes

  1. Incidence of Predefined Opioid-related Adverse Events

    The incidence of predefined opioid-related adverse events

    Time frame: From the time the informed consent is signed to the time hospital discharge order is written or through Day 30 (after surgery), which ever is sooner

07

Results

Posted May 8, 2013

Participant flow

Dates of recruitment Dec 13, 2011 to July 3, 2012

Participant flow — Overall Study
MilestonePCA/Opioid GroupEXPAREL Group
Started2022
Completed1821
Not completed21
Withdrew: Required different surgical procedures21

Outcome measures

PrimaryTotal Opioid Burden

Total opioid consumed (IV and PO) postsurgically until the hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order written or Day 30, whichever is sooner
Reported as:
Mean · mg
Total Opioid Burden
mgPCA/Opioid GroupEXPAREL
Total Opioid Burden115.00 ± 113.2756.76 ± 74.04
Statistical analysis
  • PCA/Opioid Group vs EXPAREL · least-squares mean ratio · p = 0.0251 · Ratio of geometric means: 2.62 · 95% CI 1.14 to 6.03Group 1 represents the numerator.
PrimaryHealth Economic Benefits - Total Cost of Hospitalization

Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order written or Day 30, whichever is sooner.
Reported as:
Mean · dollars
Health Economic Benefits - Total Cost of Hospitalization
dollarsPCA/Opioid GroupEXPAREL
Health Economic Benefits - Total Cost of Hospitalization11850.28 ± 6600.908766.07 ± 1048.95
Statistical analysis
  • PCA/Opioid Group vs EXPAREL · least-squares mean ratio · p = 0.02767 · Ratio of geometric means: 1.24 · 95% CI 1.03 to 1.49Group 1 represents the numerator.
SecondaryIncidence of Predefined Opioid-related Adverse Events

The incidence of predefined opioid-related adverse events

Time frame:
From the time the informed consent is signed to the time hospital discharge order is written or through Day 30 (after surgery), which ever is sooner
Reported as:
Number · Number of patients
Incidence of Predefined Opioid-related Adverse Events
Number of patientsPCA/Opioid GroupEXPAREL
Incidence of Predefined Opioid-related Adverse Events00
PrimaryHealth Economic Benefits - Length of Stay

Length of stay (LOS), recorded in hours and converted to days with one decimal of precision, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Up to Day 30
Reported as:
Median · days
Health Economic Benefits - Length of Stay
daysPCA/Opioid GroupEXPAREL Group
Health Economic Benefits - Length of Stay4.9 (3.9 to 6.7)2.0 (1.9 to 3.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCA/Opioid Group—4/18 (22.2%)4/18 (22.2%)
EXPAREL Group—5/21 (23.8%)7/21 (33.3%)
Most frequent serious events
Most frequent serious events
EventPCA/Opioid GroupEXPAREL Group
Abdominal painGastrointestinal disorders0/182/21
Small intestinal obstructionGastrointestinal disorders1/180/21
Wound eviscerationInjury, poisoning and procedural complications1/180/21
Wound drainageSurgical and medical procedures1/180/21
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders1/180/21
IleusGastrointestinal disorders0/181/21
Intestinal obstructionGastrointestinal disorders0/181/21
PyrexiaGeneral disorders0/181/21
Drug Seeking BehaviorPsychiatric disorders0/181/21
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPCA/Opioid GroupEXPAREL Group
Abdominal PainGastrointestinal disorders0/182/21
BradycardiaCardiac disorders1/180/21
Small Intestinal ObstructionGastrointestinal disorders1/180/21
Wound EviscerationInjury, poisoning and procedural complications1/180/21
Blood Creatine IncreasedInvestigations1/180/21
Blood Pressure IncreasedInvestigations1/180/21
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/180/21
Therapy Regimen ChangedSurgical and medical procedures1/180/21
Wound DrainageSurgical and medical procedures1/180/21
IleusGastrointestinal disorders0/181/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PCA/Opioid GroupEXPAREL GroupTotal
<=18 years000
Between 18 and 65 years151732
>=65 years5510
Age Continuous
Age Continuous(years)PCA/Opioid GroupEXPAREL GroupTotal
Mean54.1 ± 15.7752.6 ± 17.5153.3 ± 16.53
Sex: Female, Male
Sex: Female, Male(Participants)PCA/Opioid GroupEXPAREL GroupTotal
Female101424
Male10818
Region of Enrollment
Region of Enrollment(participants)PCA/Opioid GroupEXPAREL GroupTotal
United States202242
08

Study locations

1 site
  • Atlanta Colon and Rectal Surgery
    Riverdale, Georgia 30274, United States
09

References and documents

Publications

  • Cohen SM, Vogel JD, Marcet JE, Candiotti KA. Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis. J Pain Res. 2014 Jun 24;7:359-66. doi: 10.2147/JPR.S63764. eCollection 2014. PubMed 25018650 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jul 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2011
First posted
Jan 10, 2012
Start
Dec 2011
Primary completionActual
Jul 2012
CompletionActual
Aug 2012
Results first posted
May 8, 2013
Last update
May 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01507246
Collaborators
Registrat-Mapi
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
Dec 2011
Primary completion
Jul 2012
Completion
Aug 2012
Results posted
May 8, 2013
Last update
May 8, 2013

Study contacts

Stephen Cohen, M.D.
principal investigator · Atlanta Colon and Rectal Surgery

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion